STEADY PD (Safety, Tolerability, and Efficacy Assessment of Dynacirc® CR for PD)
Enrollment for this study is complete.
The Parkinson Study Group (PSG), under the direction of Tanya Simuni, MD (Northwestern University), and Kevin Biglan, MD, MPH (University of Rochester), is conducting a multi-center, randomized, double-blind, placebo-controlled study of isradipine CR (Dynacirc® CR) in individuals with early Parkinson disease (PD) The purpose of the study is to assess the general safety and tolerability of isradipine CR, to determine effective dosage of isradipine CR and obtain pilot data on the potential effect of isradipine on slowing the progression of PD. Approximately 18 research centers across North America will enroll up to 100 subjects for 12 months each.
Isradipine CR is a medication that is approved for the treatment of high blood pressure by the Food and Drug Administration Agency (FDA), but not for the treatment of PD. Isradipine CR has been shown to have a neuroprotective effect in preclinical models of parkinsonism (poster Simuni, et al – see ref).
This study is being conducted under a research grant award from the Michael J. Fox Foundation (MJFF) and the Dixon Foundation.
For more information please contact Boston University Parkinson’s Disease and Movement Disorder Center at 617-638-7737.